Modality
Peptide
MOA
CDK4/6i
Target
TYK2
Pathway
Incretin
AMLBladder CaRSV
Development Pipeline
Preclinical
~Jan 2017
→ ~Apr 2018
Phase 1
~Jul 2018
→ ~Oct 2019
Phase 2
Jan 2020
→ Jun 2030
Phase 2Current
NCT07405434
343 pts·Bladder Ca
2021-07→TBD·Completed
NCT08221854
318 pts·AML
2020-01→2030-06·Terminated
661 total pts2 indications
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2030-06-204.2y awayPh2 Data· AML
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3
P2
Termina…
P2
Complet…
Catalysts
Ph2 Data
2030-06-20 · 4.2y away
AML
CompletedTerminated|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07405434 | Phase 2 | Bladder Ca | Completed | 343 | DOR |
| NCT08221854 | Phase 2 | AML | Terminated | 318 | OS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5767 | Pfizer | Phase 1/2 | BET | |
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| RHH-1969 | Roche | Approved | BET | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| Ivocapivasertib | Bristol-Myers Squibb | Phase 1 | BET | |
| Zorimavacamten | Bristol-Myers Squibb | Preclinical | Cl18.2 | |
| Fixatenlimab | GSK | Phase 1/2 | JAK1 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| VRT-5441 | Vertex Pharma | Phase 3 | GLP-1R | |
| Adagracapivasertib | BeiGene | NDA/BLA | BET |